VIA
CGEM icon

Virtus Investment Advisers’s Cullinan Oncology CGEM Stock Holding History

Virtus Investment Advisers’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Buy
23,883
+1,008
+4% +$15K 0.1% 235
2026
Q1 		$325K Buy
22,875
+557
+2% +$7.16K 0.09% 267
2025
Q4 		$231K Buy
22,318
+9,604
+76% +$86.6K 0.06% 357
2025
Q3 		$75.4K Buy
12,714
+2,208
+21% +$16.2K 0.02% 435
2025
Q2 		$79.1K Sell
10,506
-2,949
-22% -$23.7K 0.03% 425
2025
Q1 		$102K Buy
+13,455
New +$129K 0.03% 415

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Virtus Investment Advisers's CGEM Position: Q2 2026 in Review

Virtus Investment Advisers increased its Cullinan Oncology (CGEM) stake by 4.4% in Q2 2026, buying an estimated $15K and bringing the position to 23,883 shares worth $435K. The position accounts for 0.1% of the portfolio, ranked #235.

Virtus Investment Advisers first reported a position in CGEM in Q1 2025 and has held it in 6 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Virtus Investment Advisers held 23,883 shares of Cullinan Oncology worth $435K as of Q2 2026.
  • Virtus Investment Advisers bought 1,008 Cullinan Oncology shares in Q2 2026, an estimated $15K.
  • Cullinan Oncology made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #235 holding.
  • Virtus Investment Advisers first reported a position in Cullinan Oncology in Q1 2025 and has held it in 6 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.